← Eichor
Condition: Cellular Immunotherapy Adoptive Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Cellular Immunotherapy Adoptive

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
Phase 1 · 1 location(s) · Allegheny Singer Research Institute (also known as Allegheny · NCT07443020Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites
Phase 1/Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07435701A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T
Phase 1/Phase 2 · 13 location(s) · Cabaletta Bio · NCT04422912Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06364423A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Phase 1/Phase 2 · 17 location(s) · Nkarta, Inc. · NCT06733935Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed o
Phase 1 · 1 location(s) · University Health Network, Toronto · NCT05963217Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480928Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07598955Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Varian
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT04815356N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C
EARLY_Phase 1 · 1 location(s) · Seth Pollack · NCT07261657B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
Phase 1 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07193628Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07589530Eight-Treg Study:Trial of Adoptive Immunotherapy With Autologous ex Vivo Expanded Regulatory CD8+ T Cells in Living Dono
Phase 1 · 1 location(s) · Nantes University Hospital · NCT06777719HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Ste
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT03326921A First-In-Human Trial of pTTL in Advanced Colorectal Cancer
Phase 1/Phase 2 · 2 location(s) · Neogap Therapeutics AB · NCT05908643R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Phase 1 · 1 location(s) · Columbia University · NCT06926894Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07589517A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherap
Phase 1/Phase 2 · 22 location(s) · Nationwide Children's Hospital · NCT05634369Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis
Phase 1/Phase 2 · 2 location(s) · Catherine Bollard · NCT03594981Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627711REgulatory T Cell Therapy to Achieve Immunosuppression REduction
Phase 2 · 7 location(s) · Singulera Therapeutics Inc. · NCT06552169Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
Phase 1 · 1 location(s) · David Bartlett, MD · NCT07192900A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma
Phase 2 · 3 location(s) · Malaghan Institute of Medical Research · NCT06486051E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Phase 1/Phase 2 · 2 location(s) · Christian Hinrichs · NCT05639972CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Rel
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT07328503Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07467863R-MVST Cells for Treatment of Viral Infections
Phase 1 · 1 location(s) · Columbia University · NCT05183490Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarco
Phase 3 · 2 location(s) · Takara Bio Inc. · NCT07174427Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07510802
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.